Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

569 result(s) found, displaying 26 to 50

  • AusPAR: Vumerity

    Australian public assessment report (AusPar)
    New AusPAR for VUMERITY (diroximel fumarate) to reduce relapses and delay progression of disability in multiple sclerosis patients.

  • AusPAR: Jemperli

    Australian public assessment report (AusPar)
    New AusPAR for Jemperli (dostarlimab) for the treatment of mismatch repair deficient endometrial cancer.

  • AusPAR: Vyxeos

    Australian public assessment report (AusPar)
    New AusPAR for Vyxeos (daunorubicin and cytarabine) for the treatment of acute myeloid leukaemia.

  • AusPAR: Vaxelis

    Australian public assessment report (AusPar)
    New AusPAR for Vaxelis (DTPa5-Hep B-IPV-Hib) for primary and booster vaccination.

  • AusPAR: Voxzogo

    Australian public assessment report (AusPar)
    AusPAR for Voxzogo (vosoritide) for the treatment of achondroplasia.

  • AusPAR: Ngenla

    Australian public assessment report (AusPar)
    AusPAR for Ngenla (somatrogon) for treatment of paediatric patients with growth disturbance due to insufficient growth hormone.

  • AusPAR: Evusheld

    Australian public assessment report (AusPar)
    AusPAR for Evusheld (tixagevimab and cilgavimab) for treatment of adults with COVID-19.

  • AusPAR: Kozenis

    Australian public assessment report (AusPar)
    AusPAR for Kozenis (tafenoquine) for prevention of relapse of Plasmodium vivax malaria in combination with chloroquine.

  • AusPAR: Nexviazyme

    Australian public assessment report (AusPar)
    AusPAR for NEXVIAZYME (avalglucosidase alfa) for long-term enzyme replacement therapy for the treatment of Pompe disease.

  • AusPAR: Truseltiq

    Australian public assessment report (AusPar)
    AusPAR for Truseltiq (infigratinib) for treatment of adults with metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.

  • AusPAR: Saphnelo

    Australian public assessment report (AusPar)
    AusPAR for SAPHNELO (anifrolumab) as add on treatment of adult patients with moderate to severe, active systemic lupus erythematosus.

  • AusPAR: Flucelvax Quad

    Australian public assessment report (AusPar)
    AusPAR for Flucelvax Quad (quadrivalent influenza vaccine) for the prevention of influenza.

  • AusPAR: Rybelsus

    Australian public assessment report (AusPar)
    Rybelsus (semaglutide) has been approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

  • AusPAR: Yuflyma

    Australian public assessment report (AusPar)
    AusPAR for Yuflyma (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis etc.

  • AusPAR: Cosentyx

    Australian public assessment report (AusPar)
    AusPAR for Cosentyx (secukinumab) for the treatment of plaque psoriasis, psoriatic arthritis and axial spondyloarthritis etc.

  • Isturisa

    Australian public assessment report (AusPar)
    AusPAR for Isturisa (osilodrostat as phosphate) for the treatment of endogenous Cushing’s syndrome in adults.

  • AusPAR: Dazalex SC

    Australian public assessment report (AusPar)
    AusPAR for DARZALEX SC (daratumumab) for the treatment of light chain AL amyloidosis

  • AusPAR: Vaxneuvance

    Australian public assessment report (AusPar)
    AusPAR for Vaxneuvance (pneumococcal 15-valent conjugate vaccine (CRM197 protein), adsorbed) for the prevention of pneumococcal disease.

  • AusPAR: Sogroya

    Australian public assessment report (AusPar)
    AusPAR for SOGROYA (somapacitan) indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency.

  • AusPAR: Tozinameran

    Australian public assessment report (AusPar)
    New AusPAR for Comirnaty (tozinameran) for the prevention of COVID-19 in individuals 6 months of age and older.

  • AusPAR: Libtayo

    Australian public assessment report (AusPar)
    AusPAR for LIBTAYO (cemiplimab) for treatment of adult patients with locally advanced and metastatic basal cell carcinoma.

  • AusPAR: Zeposia

    Australian public assessment report (AusPar)
    AusPAR for Zeposia (ozanimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.

  • AusPAR: Libtayo

    Australian public assessment report (AusPar)
    New AusPAR for LIBTAYO (cemiplimab) as first-line treatment of adult patients with non-small cell lung cancer.